Inosia Capsules
Natural health product licensed in Canada
- Licence holder
- Technologies Yad Inc.
- NPN or DIN-HM
- 80075282
- Status
- Inactive licence
- Licence date
- 26 January 2017
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Glycyrrhiza glabra L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| D-Chiro-inositol Source : D-Chiro-inositol | 7.5 milligramme | Not calculated |
| Myo-Inositol Source : Inositol | 300 milligramme | Not calculated |
| Chrome Source : Picolinate de chrome (III) | 50 microgrammes | Not calculated |
| Vanadium Source : Produit de chélation de vanadium et de protéine végétale hydrolysée (PVH) | 18.75 microgrammes | Not calculated |
| Vitex agnus-castus Source : Fruit | 40.5 milligramme | Not calculated |
| Paeonia lactiflora Source : Racine | 100 milligramme | Not calculated |
| Glycyrrhiza glabra Source : Racine | 15 milligramme | Not calculated |
| Actaea racemosa Source : Racine | 5 milligramme | Not calculated |
| N-acétyl-l-cystéine Source : N-Acétyl-L-cystéine | 25 milligramme | Not calculated |
Non-medicinal ingredients
Phosphate de dicalcium dihydrate, Stéarate de magnésium, Microcrystalline cellulose, Eau purifiée, Dioxyde de silicium, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Used in Herbal Medicine to help relieve premenstrual symptoms. Used in Herbal Medicine as a hormone normaliser to help stabilise menstrual cycle irregularities. Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flashes.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80075282
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.